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a b s t r a c t
This work provides an improvement of the approach using Monte Carlo simulation for the
Amersham Model 6711 125I brachytherapy seed source, which is well known by many the-
oretical and experimental studies. The source which has simple geometry was researched
with respect to criteria of AAPM Tg-43 Report. The approach offered by this study involves
determination of differential dose contributions that come from virtual partitions of a mas-
sive radioactive element of the studied source to a total dose at analytical calculation point.
Some brachytherapy seeds contain multi-radioactive elements so the dose at any point is a
total of separate doses from each element. It is momentous to know well the angular and
radial dose distributions around the source that is located in cancerous tissue for clinical
treatments. Interior geometry of a source is effective on dose characteristics of a distribu-
tion. Dose information of inner geometrical structure of a brachytherapy source cannot be
acquired by experimental methods because of limits of physical material and geometry in
the healthy tissue, so Monte Carlo simulation is a required approach of the study. EGSnrc
Monte Carlo simulation software was used. In the design of a simulation, the radioactivesource was divided into 10 rings, partitioned but not separate from each other. All differ-
ential sources were simulated for dose calculation, and the shape of dose distribution was
determined comparatively distribution of a single-complete source. In this work anisotropy
function was examined also mathematically.
© 2010 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
3. Introduction
n general deﬁnition, brachytherapy is a placement of radioac-
ive sources into cancerous tissue volume at single or multiple
ocations. It (sometime it is mentioned as Curie therapy)1 uses
adiationof lowenergy that is taken into a capsule (this system
s named seed) in cancer treatment.
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While low-energy, photon-emitting brachytherapy sources
have been used to treat cancers involving a variety of anatomi-
cal sites, including eyeplaque therapy for choroidalmelanoma
andpermanent lung implants,2 theirmost frequent indication
today is for the treatment of prostate cancer. Prostate can-
cer is the most frequent type of cancer in men in the United
Stateswith approximately 180,000 new incident cases per year
and an annual death rate of about 37,000.4 While approxi-
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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mately 60% of new cases are conﬁned to the organ at time
of diagnosis, only about 2.2% of these new cases were treated
with brachytherapy in 1995. Since that time, the percentage
has increased to about 30% of all eligible patients receiving
implants in current practice.5
The aim is to apply radiation with optimum dose on can-
cer tissues with minimum damage to healthy ones. In clinical
treatments, scientiﬁc data are taken as criteria in the use
of brachytherapy sources and devices. Especially simulation
studies are momentous before treatment planning as pre-
examination.
Knowledge of dose distribution around radioactive sources
employed in brachytherapy implants is necessary in order to
provide a more solid basis when developing a clinical strat-
egy. The AAPM TG-43 Report recommends dosimetry protocol
based on measured or measurable quantities and decouples
number of interrelated quantities.6 The protocol allows two-
dimensional dose calculations aroundcylindrically symmetric
sources.7
Source geometry and internal construction arehighlyman-
ufacturer speciﬁc. Source models vary from one another with
regard to weld thickness and type, radioactivity carrier con-
struction, presence of radio-opaque material with sharp or
rounded edges, presence of silver (which produces character-
istic X-rays that modify the photon spectrum), and capsule
wall thickness. All of these properties can affect the dosi-
metric characteristics of the source.5 Based on the results of
Williamson,8 purely Monte Carlo estimates of the transverse-
axis dose-rate per unit air-kerma strength typically have
uncertainties of 2–3% at 1 cm and 3–5% at 5 cm, depend-
ing on the type and magnitude of internal seed geometric
uncertainties. Since relatively little has beenpublishedonesti-
mation of systematic uncertainties of Monte Carlo-based dose
estimation.5
In this work an approach was examined to lead to deter-
mining internal geometry effects on dose distribution. Along
radioactive source axis in bachytherapy seed, radio-opaque
markerwhich is coated by radioactivematerial (125I) andactive
Fig. 1 – Illustration of geometry assumed in the dose
calculation formalism. Angle ˇ is that subtended by the
active length at point P. The reference point is represented
by P(r0, 0).5diotherapy 1 5 ( 2 0 1 0 ) 69–74
element have cylindrical geometry basically. According to the
approach, the cylinder was cut into 10 partitions in Monte
Carlo simulation by geometry design routine of the software.
EGSnrc–dosrznrc was used for simulation of dose calculation
in water phantom. There can be found several softwares for
MonteCarlo simulation.Apart fromEGSnrcCode,MCNP4Code
is commonly used for brachytherapy studies.9
In view of its suitable radiation characteristics, such as
∼27.4–35keV X and gamma radiations, reasonably long half-
life of∼60days, and ease of production inmediumﬂuxnuclear
reactors, 125I is considered to be one of the best isotopes
among the available options for use in both eye and prostate
brachytherapy. 125I seed sources are also being tried for the
treatment of various tumor sites, because their low-energy
photon emissions cause a rapid decrease in dose with increas-
ing distance and thereby minimize the dose to adjacent vital
organs.10,11
1.1. General formalism for two-dimensional case
We restrict consideration to cylindrically symmetric sources,
such as that illustrated in Fig. 1. For such sources, the dose
distribution is two-dimensional and can be described in terms
of a polar coordinate systemwith its origin at the source center
where r is the distance to the point of interest and  is the angle
with respect to the long axis of the source (Fig. 1).
P(r0, 0) is named a reference point. At this point it assumed
that factors – except radial effects – that affect the dose rate
are negligible. At any point the dose rate is given by
D˙(r, ) = Sk
G(r, )
G(r0, 0)
g(r)F(r, )
where Sk is air-kerma strength,  dose rate constant, and
G(r, ) geometry function that is completely mathematical
formalism dependent on source dimensions. The radial dose
function, g(r), accounts for the effects of absorption and scat-
ter in the medium along the transverse axis of the source. It
is deﬁned as:
g(r) = D˙(r, /2)G(1, /2)
D˙(1, /2)G(r, /2)
Theanisotropy functionaccounts for theanisotropyof dose
distribution around the source, including the effects of absorp-
tion and scatter in the medium. It is deﬁned as:
F(r, ) = D˙(r, )G(r, /2)
D˙(r, /2)G(r, )
1.2. Radioactive source–seed
125I is produced when 124Xe absorbs a neutron, and then
decays via electron capture. 125I itself decays with a half life of
59.4 days, by electron capture to the ﬁrst excited state of 125Te,
which undergoes internal conversion 93% of the time and
otherwise emits a 35.5 keV gamma ray. The electron capture
and internal conversion processes give rise to characteristic
X-rays.5
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Fig. 2 – Source symmetry on polar (R, Z) system: P(r, ) =P′(r,

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Fig. 4 – Divisions of radioactive material of the seed on a
cylindrical proﬁle.
decrease uncertainty of dose. It means that bigger volumes), where P is dose calculation point in the designed voxel.
.3. Simulation design: for source
sing EGSnrc-MP code, it is possible to design cylindrical
eometries and virtual objects. In the code, the phantom and
he seed were designed as coaxial (equal axis) in cylindri-
al coordinate system. To limit cylinders, planar slabs were
sed. By using slabs and rings, voxels were performed in
ater phantom. These small volumes include dose calcula-
ion points. Voxels were selected as small as. Simulation was
erformed in 0–90◦ angular region of analytic system since the
eed 6711 is symmetrical between 0◦ and 180◦ to vertical axle.
t is assumed that all dose points of 0–90◦ region are equal to
0–180◦ region’s points (Fig. 2).
.4. Radioactive seed geometry and physical properties
ccurate knowledge of internal source geometry and con-
truction details is especially important for Monte Carlo
odeling (Fig. 3).
Radioactive material with 0.3 cm length was divided into
0 geometric pieces with 0.03 cm length. On the source axe,
ivision lines were located at [−0.15, −0.12], [−0.12, −0.09],
−0.09, −0.06], [0.06, −0.03], [−0.03, 0], [0,0.03], [0.03, 0.06], [0.06,
.09], [0.09, 0.12], [0.12, 0.15] lengths on the [−0.15, 0.15] length
Fig. 4).
This division process (Fig. 5) provides a similarity between
eeds with multi-radioactive source and simple seeds like
odel 6711 (Fig. 6a) and Theragenics200 palladium (Fig. 6b).
xample source Theragenics has two radioactive sources in
ts capsule (Fig. 6b). Calculations relate to Theragenic source
re made by using differential doses of two separate sources.
Fig. 3 – Physical dimensions of AmeFig. 5 – Three-dimensional illustration of the seed-source
geometry.
1.5. Phantom and voxel modeling
Phantom where dose is calculated was modeled as a cylinder
that coated the seed. Geometry is designed in association with
the seed and source because planes cut all cylinders of source
and phantom together. Modeling was performed as a source-
phantom system. Voxels (this term is used in dosimetric area
meaning a small volume of phantom and derived from a two-
dimensional pixel term for three dimensions), which include
analytic point of calculation, were located around the seed on
polar coordinates. Instead of a cubic voxel, equivalent rings
were used (Fig. 7) because of their cylindrical symmetry towere acquired for every voxel. Intersections of vertical and
horizontal lines produce cubic intersections (Fig. 8). Ring inter-
sections go through these sections (Table 1).
rsham Model 6711 125I source.5
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Fig. 6 – (a and b) Intersections of Model 6711 and palladium Theragenic200 seeds.
Fig. 7 – Equivalent rings of voxels on polar points.
Table 1 – 125I decay spectrum (NNDC).
Decay y(i) (Bq-s)−1 Photon energy (MeV)
1 6.68×10−02 3.549×10−02
ce-K, 1 8.02×10−01 3.678×10−03
ce-L, 1 1.08×10−01 3.055×10−02
ce-M, 1 2.15×10−02 3.449×10−02
K1 X-ray 7.44×10−01 2.747×10−02
K2 X-ray 4.00×10−01 2.720×10−02
K X-ray 2.59×10−01 3.100×10−02
L X-ray 1.49×10−01 3.770×10−03
Auger-K 2.00×10−01 2.270×10−02
Fig. 8 – This schema represents rings and slabs. Rings and
slabs are produced from intersection of planes and cylinder
shells. Intersections of vertical and horizontal lines
Table 2 – For r=2 cm D(2, )/D(2, /2) of divisions.

1 2 3 4 5
10 0.42 0.42 0.42 0.43 0.44
20 0.58 0.59 0.58 0.61 0.63
30 0.68 0.69 0.68 0.71 0.73
40 0.75 0.77 0.76 0.78 0.81
50 0.83 0.84 0.83 0.86 0.88
60 0.89 0.89 0.88 0.90 0.91
70 0.96 0.96 0.94 0.95 0.96
80 0.98 0.98 0.95 0.96 0.96produce cubic sections.
2. Mathematical approach
This work also offers a mathematical deduction for anisotropy
function upon divided dose calculations. Differential doses
can be added as:
D˙(r, ) =
∑
i
D˙i(r, )
Anisotropy function is formed:
∑
D˙ (r, )F(r, ) = D˙(r, )G(r, /2)
D˙(r, /2)G(r, )
→ F(r, ) = i
i
∑
D˙i(r, /2)
× G(r, /2)
G(r, )
Div
6 7 8 9 10
0.46 0.48 0.50 0.51 0.62
0.65 0.67 0.70 0.72 0.84
0.75 0.78 0.80 0.83 0.95
0.83 0.86 0.89 0.90 1.04
0.89 0.92 0.94 0.97 1.08
0.93 0.95 0.96 0.98 1.06
0.97 0.98 0.99 1.00 1.05
0.96 0.96 0.97 0.97 0.99
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Table 3 – For r=3 cm D(3, )/D(3, /2) of divisions.
 Div
1 2 3 4 5 6 7 8 9 10
10 0.47 0.48 0.47 0.49 0.5 0.51 0.51 0.52 0.53 0.63
20 0.62 0.62 0.62 0.63 0.64 0.66 0.67 0.68 0.7 0.81
30 0.76 0.76 0.76 0.78 0.79 0.8 0.82 0.83 0.86 0.97
40 0.83 0.83 0.83 0.84 0.86 0.87 0.89 0.9 0.92 1.04
50 0.88 0.88 0.89 0.89 0.91 0.92 0.93 0.94 0.96 1.07
60 0.93 0.93 0.93 0.94 0.94 0.95 0.96 0.97 0.98 1.07
70 0.93 0.92 0.91 0.92 0.92 0.92 0.93 0.93 0.94 0.99
80 0.95 0.93 0.92 0.92 0.92 0.92 0.92 0.91 0.92 0.94
Table 4 – For r=4 cm D(4, )/D(4, /2) of divisions.
 Div
1 2 3 4 5 6 7 8 9 10
10 0.56 0.57 0.57 0.57 0.58 0.58 0.59 0.6 0.61 0.71
20 0.75 0.76 0.75 0.76 0.78 0.79 0.8 0.81 0.83 0.94
30 0.82 0.83 0.82 0.84 0.84 0.84 0.85 0.86 0.88 0.98
40 0.88 0.89 0.89 0.89 0.9 0.9 0.91 0.93 0.95 1.05
50 0.94 0.95 0.94 0.95 0.96 0.96 0.96 0.98 0.99 1.08
60 0.96 0.97 0.96 0.96 0.96 0.95 0.96 0.97 0.98 1.3
70 1.02 1.02 1.01 1.01 1.01 1 1 1.01 1.02 1
80 0.99 0.99 0.97 0.97 0.97 0.96 0.95 0.96 0.96 1.37
Table 5 – For r=5 cm D(5, )/D(5, /2) of divisions.
 Div
1 2 3 4 5 6 7 8 9 10
10 0.59 0.59 0.6 0.61 0.61 0.62 0.63 0.76 0.76 0.75
20 0.69 0.69 0.71 0.72 0.73 0.74 0.76 0.77 0.78 0.86
30 0.77 0.77 0.79 0.8 0.81 0.82 0.83 0.84 0.85 0.92
40 0.83 0.84 0.86 0.86 0.88 0.89 0.89 0.9 0.91 0.98
0.92 0.93 0.94 0.95 0.96 1.02
0.96 0.97 0.97 0.97 0.98 1.03
0.98 0.98 0.98 0.98 0.99 1.01
1 1 1 1 1 1
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c50 0.89 0.89 0.9 0.91
60 0.93 0.93 0.95 0.95
70 0.97 0.96 0.98 0.97
80 1 0.99 1 0.99
.1. Differential function deﬁnitions
hese deﬁnitions are offered by this study
i(r, ) =
D˙(r, )∑
i
D˙i(r, /2)
Total anisotropy function can be written as:
(r, ) =
∑
i
Fi(r, ) ×
G(r, /2)
G(r, )
here the “i” index is a representation of a segment number
f the radioactive source. It was seen from calculation results
Tables 2–5) that for every  angle in the same radial value, the
ractions corresponding to the divisions were approximately
qual to each other for distant divisions to calculation point.
his speciﬁcation can be shown. Bold values in the tables pro-
ide constant approach.D˙1(rn, m)
D˙1(rn, /2)
= D˙2(rn, m)
D˙2(rn, /2)
= D˙3(rn, m)
D˙3(rn, /2)
= · · · = D˙N(rn, m)
D˙N(rn, /2)
= C
here m=10◦, 20◦, 30◦, . . ., 90◦, n is a distance index of dose
alculation point to the source in cm unit and C is constant.Fig. 9 – For 2 cm radial values, angular dose distributions of
virtual source divisions.
3. ConclusionFor 2, 3, 4 and 5 cm radial values, angular dose distributions of
virtual source divisions were determined (Figs. 9–12).
To shape aimed proﬁle of dose multi-sources and maker
are designed for such seeds (Fig. 6b). In this study ﬁrstly it
74 reports of practical oncology and ra
Fig. 10 – For 3 cm radial values, angular dose distributions
of virtual source divisions.
Fig. 11 – For 4 cm radial values, angular dose distributions
of virtual source divisions.
Fig. 12 – For 5 cm radial values, angular dose distributions
of virtual source divisions.
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11. Monge MR, Nag S, Nieroda C, Martin EW. Iodine-125
brachytherapy in the treatment of colorectal
adenocarcinoma metastatic to the lever. Cancer
1999;85(6):1218–25.diotherapy 1 5 ( 2 0 1 0 ) 69–74
is aimed that investigation novel designation approaches to
acquire uniform dose proﬁle along seed cylinder in tissue.
Constant value that is suggested in mathematical repre-
sentation of anisotropy function is completely dependent on
source speciﬁcations (geometry). C constant deduction cannot
be seen clearly for distance longer than 3 cm (Table 2). Doses
decrease rapidly beyond 1 cm for low energies of x photons
of 125I so statistical errors increase. This situation causes non
sensitive dose calculation.
Dose distributions of divisions are parallels until 10th divi-
sion (Figs. 9–12) for different angles in several radial distances
(2, 3, 4 and 5 cm). Ends of the source are more effective on
distributions. It means that the most important contribution
is made by the end regions of source cylinder. This must be
taken into account in source designs.
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